Profile data is unavailable for this security.
About the company
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
- Revenue in USD (TTM)1.34m
- Net income in USD-72.21m
- Incorporated1998
- Employees25.00
- LocationNorthwest Biotherapeutics IncSUITE 800, 4800 MONTGOMERY LANEBETHESDA 20814United StatesUSA
- Phone+1 (240) 497-9024
- Fax+1 (302) 636-5454
- Websitehttps://nwbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PepGen Inc | 0.00 | -80.33m | 529.37m | 64.00 | -- | 2.95 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 530.98m | 100.00 | -- | 5.35 | -- | 6.28 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| SIGA Technologies Inc | 157.02m | 79.26m | 532.00m | 45.00 | 6.82 | 3.22 | 6.66 | 3.39 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Altimmune Inc | 410.00k | -92.77m | 532.48m | 59.00 | -- | 3.08 | -- | 1,298.72 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 540.23m | 100.00 | -- | 1.50 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 541.44m | 75.00 | -- | 2.29 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Third Harmonic Bio Inc | 0.00 | -29.60m | 545.04m | 31.00 | -- | 2.03 | -- | -- | -0.7475 | -0.7475 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -10.53 | -- | -10.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 545.22m | 25.00 | -- | -- | -- | 408.10 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Lexeo Therapeutics Inc | 0.00 | -69.42m | 547.88m | 58.00 | -- | 2.99 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 2.59m | -246.63m | 551.40m | 452.00 | -- | -- | -- | 212.57 | -4.41 | -4.41 | 0.047 | -2.54 | 0.0104 | -- | -- | 5,738.94 | -98.55 | -83.26 | -111.44 | -93.77 | 77.14 | -- | -9,507.71 | -135,982.00 | 7.80 | -5.29 | 1.46 | -- | -- | -- | -1.96 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 553.82m | 74.00 | -- | 3.25 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Celcuity Inc | 0.00 | -73.45m | 554.60m | 55.00 | -- | 3.64 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 557.42m | 126.00 | -- | -- | -- | 4.22 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 557.82m | 121.00 | -- | 2.14 | -- | 11.15 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 564.88m | 380.00 | -- | 7.62 | -- | 3.63 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Data as of May 31 2024. Currency figures normalised to Northwest Biotherapeutics Inc's reporting currency: US Dollar USD
0.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Moloney Securities Asset Management LLCas of 31 Mar 2024 | 379.46k | 0.03% |
| Opus Capital Group LLCas of 31 Mar 2024 | 60.15k | 0.01% |
| Williams Jones Wealth Management LLCas of 31 Mar 2024 | 40.00k | 0.00% |
| MariPau Wealth Management LLCas of 31 Mar 2024 | 39.49k | 0.00% |
| Ethos Financial Group LLCas of 31 Mar 2024 | 23.70k | 0.00% |
| Lee, Danner & Bass, Inc.as of 31 Dec 2023 | 20.00k | 0.00% |
| Advisors Management Group, Inc.as of 31 Mar 2024 | 10.27k | 0.00% |
| Manulife Investment Management Ltd.as of 31 Mar 2024 | 3.46k | 0.00% |
| Coston, McIsaac & Partners, Inc.as of 31 Mar 2024 | 1.00k | 0.00% |
| Sentinus LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 30 May 2024Source: FactSet Research Systems Inc.
